Chronic Myeloproliferative Disorders

7
Pipeline Programs
3
Companies
8
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
2
0
1
2
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

U
ONDANSETRONApproved
ondansetron
Unknown Company
oral2007
U
ZUPLENZApproved
ondansetron
Unknown Company
oral2010

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
2 programs
1
1
ondansetronPhase 31 trial
Compound 506U78Phase 11 trial
Active Trials
NCT00004239Terminated10Est. Jan 2002
NCT00006348Completed100Est. Sep 2001
Knight Therapeutics
Knight TherapeuticsQC - Montréal
5 programs
1
2
anti-thymocyte globulinPhase 21 trial
imatinib mesylatePhase 21 trial
therapeutic allogeneic lymphocytesPhase 1/21 trial
filgrastimN/A1 trial
microarray analysisN/A1 trial
Active Trials
NCT00253552Terminated4Est. May 2006
NCT00900055Completed213Est. Aug 2016
NCT00245037Completed147Est. Aug 2015
+2 more trials
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
immunosuppressive therapyN/A1 trial
Active Trials
NCT00813501TerminatedEst. Jun 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alliance Pharmaceuticalsondansetron
Knight Therapeuticsanti-thymocyte globulin
Knight Therapeuticsimatinib mesylate
Knight Therapeuticstherapeutic allogeneic lymphocytes
Alliance PharmaceuticalsCompound 506U78
City Therapeuticsimmunosuppressive therapy
Knight Therapeuticsfilgrastim
Knight Therapeuticsmicroarray analysis

Clinical Trials (8)

Total enrollment: 684 patients across 8 trials

NCT00006348Alliance Pharmaceuticalsondansetron

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

Start: Oct 2000Est. completion: Sep 2001100 patients
Phase 3Completed
NCT00281879Knight Therapeuticsanti-thymocyte globulin

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Start: Feb 2006Est. completion: Mar 2008200 patients
Phase 2Terminated
NCT00245128Knight Therapeuticsimatinib mesylate

Imatinib Mesylate in Treating Patients With Myelofibrosis

Start: Aug 2005Est. completion: Oct 201110 patients
Phase 2Terminated
NCT00245037Knight Therapeuticstherapeutic allogeneic lymphocytes

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Start: Jun 2005Est. completion: Aug 2015147 patients
Phase 1/2Completed
NCT00004239Alliance PharmaceuticalsCompound 506U78

506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

Start: Dec 1999Est. completion: Jan 200210 patients
Phase 1Terminated
NCT00813501City Therapeuticsimmunosuppressive therapy

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

Start: Jun 2008Est. completion: Jun 2010
N/ATerminated
NCT00253552Knight Therapeuticsfilgrastim

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

Start: May 2004Est. completion: May 20064 patients
N/ATerminated
NCT00900055Knight Therapeuticsmicroarray analysis

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

Start: Jun 1975Est. completion: Aug 2016213 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space